Chen, Hsiao-Yun
Durmaz, Yavuz T.
Li, Yixiang
Sabet, Amin H. http://orcid.org/0000-0001-6010-3632
Vajdi, Amir
Denize, Thomas
Walton, Emily
Laimon, Yasmin Nabil
Doench, John G. http://orcid.org/0000-0002-3707-9889
Mahadevan, Navin R.
Losman, Julie-Aurore http://orcid.org/0000-0002-3790-2660
Barbie, David A.
Tolstorukov, Michael Y.
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Sen, Triparna
Signoretti, Sabina
Oser, Matthew G. http://orcid.org/0000-0003-2047-0969
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (CI-101-19)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA222657)
Kaplan Family Fund
Article History
Received: 21 September 2021
Accepted: 8 July 2022
First Online: 25 August 2022
Competing interests
: M.G.O. has (currently or previously) sponsored research agreements (SRAs) with Takeda, Eli Lilly, Novartis, Circle Pharma, and Bristol Myers Squibb. None of these SRAs were used to fund this work. D.A.B. reports grants from Xsphera Biosciences, Takeda, Gilead Sciences, Novartis Oncology, BMS, and Lilly/LOXO outside the submitted work, and personal fees from Qiagen/N of One, Tango Biosciences, Exo Therapeutics outside the submitted work. T.S. has research funding from Jazz Pharmaceuticals. C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, D2G Oncology, Genentech/Roche, Ipsen, Jazz, Kowa, Merck, and Syros, and serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. The remaining authors declare no competing interests.